ACP-196

Phase 2Small molecule

AAcerta Pharma BV

ACP-196 is one of 104 small molecule programs targeting Mantle Cell Lymphoma (MCL). It is currently in Phase 2.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mantle Cell Lymphoma (MCL)Active, not recruiting

Relapsed/refractoryActive, not recruiting

Glioblastoma MultiformeActive, not recruiting

Mantle Cell Lymphoma (MCL)Phase 2

Active, not recruiting

Relapsed/refractoryPhase 2

Active, not recruiting

Glioblastoma MultiformePhase 2

Active, not recruiting

Competition

Competitive Landscape

64 competitors in Relapsed/refractory

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

9 2

Rituxan

Roche

Phase 2

9 3

Venclexta

AbbVie

Phase 2

8 4

Fludara

Sanofi

Phase 2

7 5

Opdivo

Bristol-Myers Squibb

Phase 2

4 6

Keytruda

Merck & Co.

Phase 2

4 7

Gemzar

Johnson & Johnson

Phase 2

2 8

Adcetris

Pfizer

Phase 2

2 9

Velban

Eli Lilly

Phase 2

1 10

Braftovi

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pancreatic Cancer2 trials

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

Completed·AAcerta Pharma BV·Phase 2·NCT02362048·77 enrolled

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

Terminated·AAcerta Pharma BV·Phase 2·NCT02570711·3 enrolled

Glioblastoma Multiforme1 trial

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Active, not recruiting·AAcerta Pharma BV·Phase 1/2·NCT02586857·24 enrolled

Hepatic Insufficiency1 trial

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

Completed·AAcerta Pharma BV·Phase 1·NCT04867941·18 enrolled

Tics1 trial

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

Completed·AAcerta Pharma BV·Phase 1·NCT04876807·36 enrolled

Relapsed/Refractory1 trial

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Active, not recruiting·AAcerta Pharma BV·Phase 2·NCT02717611·60 enrolled

5 more indications

Drug Interactions1 trial

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

Completed·AAcerta Pharma BV·Phase 1·NCT04901923·59 enrolled

Interaction1 trial

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

Completed·AAcerta Pharma BV·Phase 1·NCT04914936·72 enrolled

Adult1 trial

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Completed·AAcerta Pharma BV·Phase 1·NCT04867980·48 enrolled

Bladder Cancer1 trial

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

Completed·AAcerta Pharma BV·Phase 2·NCT02351739·78 enrolled

Mantle Cell Lymphoma (MCL)1 trial

An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma

Active, not recruiting·AAcerta Pharma BV·Phase 2·NCT02213926·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for ACP-196. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ACP-196 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ACP-196. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Acerta Pharma BV company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAcerta Pharma BV

ACP-196

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pancreatic Cancer2 trials

Glioblastoma Multiforme1 trial

Hepatic Insufficiency1 trial

Tics1 trial

Relapsed/Refractory1 trial

Drug Interactions1 trial

Interaction1 trial

Adult1 trial

Bladder Cancer1 trial

Mantle Cell Lymphoma (MCL)1 trial

References

Drug Info

Quick Facts

Related News